• VistaGen Therapeutics cut approximately 31% of its workforce on October 26, 2026, to reduce operating expenses and preserve capital.
• The reduction is expected to save approximately $3.2 million annually in salary and benefits, with estimated severance and termination costs of $1 million.
• Retained capabilities support fasedienol’s registration-directed U.S. Phase 3 development for social anxiety disorder and potential future development of two Phase 2 candidates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-068627), on October 30, 2026, and is solely responsible for the information contained therein.